MENU
MENUVolume : VII, Issue : VIII, August - 2018
Reinvention of clinical use of Urine glucose test as a predictor of glucose lowering efficacy of SGLT2 inhibitor therapy as oral hypoglycemic agent in Type 2 diabetes mellitus.
Dr Kapil Deb Lahiri
Abstract :
Backgrounds: To reinvent the clinical use of Urine glucose test as a predictor of glucose
lowering efficacy of oral SGLT2 inhibitor therapy in Type 2 diabetes mellitus.
Methods: Forty-six (Group A) new T2DM & 42 (Group B) new T2DM with urine glucose test
results (+) & (+++) respectively were given 2000 mg of metformin sustained release & 10 mg
of dapagliflozin (SGLT2 inhibitor) per day who have baseline HbA1c of 7.8
0.3% &7.9 0.3%respectively and fasting plasma glucose of 18015mg/dl & 18414mg/dl respectively. Theywere followed up at an interval of three months up to six months with HbA1c, fasting plasmaglucose & urine glucose test.
Results: Better HbA1c and fasting plasma glucose reductionwas seen in Group A than Group B patients.
Conclusion: urine glucose testing can predict the glucose lowering efficacy of oralSGLT2 inhibitor therapy in Type 2 diabetes mellitus.
Keywords :
Article:
Download PDF
DOI : https://www.doi.org/10.36106/gjra
Cite This Article:
Dr Kapil Deb Lahiri, Reinvention of clinical use of Urine glucose test as a predictor of glucose lowering efficacy of SGLT2 inhibitor therapy as oral hypoglycemic agent in Type 2 diabetes mellitus., GLOBAL JOURNAL FOR RESEARCH ANALYSIS : Volume-7 | Issue-8 | August-2018
Number of Downloads : 364
References :
Dr Kapil Deb Lahiri, Reinvention of clinical use of Urine glucose test as a predictor of glucose lowering efficacy of SGLT2 inhibitor therapy as oral hypoglycemic agent in Type 2 diabetes mellitus., GLOBAL JOURNAL FOR RESEARCH ANALYSIS : Volume-7 | Issue-8 | August-2018
